๐๐๐ง๐ฎ๐๐ซ๐ฒ ๐๐๐ฐ๐ฌ ๐๐จ๐ฎ๐ง๐ ๐๐ฉ ๐ ๐๐๐ฎ๐ฌ๐๐ก + ๐๐จ๐ฆ๐ ๐๐๐ช๐ฎ๐ข๐ซ๐๐ฌ...
๐๐ ๐๐๐ฐ๐ฌ
๐ ๐๐๐ฎ๐ฌ๐๐ก + ๐๐จ๐ฆ๐ ๐๐๐ช๐ฎ๐ข๐ซ๐๐ฌ ๐๐ก๐ข๐ญ๐๐๐๐ฉ ๐๐ข๐จ๐ฌ๐๐ข๐๐ง๐๐๐ฌ
Bausch + Lomb has announced the acquisition of Whitecap Biosciences, LLC, which is currently developing 2 therapies for potential use in glaucoma and geographic atrophy (GA). This acquisition aims to enhance Bausch + Lombโs clinical-stage pipeline with innovative treatments targeting two of the leading causes of blindness in ophthalmology.
Yehia Hashad MD, MD, Chief Medical Officer and Executive Vice President of research & development at Bausch + Lomb, stated, โGlaucoma and geographic atrophy are two areas where we believe that dramatic improvement is possible. Whitecap Biosciencesโ investigational medicines show real promise when it comes to slowing vision loss and perhaps even improving vision for patients with glaucoma, which would be a long-overdue breakthrough.โ
๐ ๐๐ฏ๐ข๐๐๐๐ ๐๐๐๐ฎ๐ซ๐๐ฌ $207.5๐ ๐ญ๐จ ๐๐๐ฏ๐๐ง๐๐ ๐๐๐-104 ๐๐จ๐ซ ๐๐๐จ๐ ๐ซ๐๐ฉ๐ก๐ข๐ ๐๐ญ๐ซ๐จ๐ฉ๐ก๐ฒ ๐๐ซ๐๐๐ญ๐ฆ๐๐ง๐ญ
Aviceda Therapeutics has successfully secured $207.5 million in Series C financing to support its ongoing Phase 2b and Phase 3 clinical trials of AVD-104 for geographic atrophy (GA).
The ongoing phase 2b/3 trial is evaluating the safety and efficacy of high and low dose AVD-104 compared to avacincaptad pegol (IZERVAY) in patients with GA. Enrolment for this study was completed in September 2024, and 12-month primary endpoint data is anticipated in the second half of 2025. With the backing of this investment, Aviceda is well-positioned to advance AVD-104 through pivotal clinical trials, bringing it closer to potential regulatory approval.
